Nils Richter

Treatment continuation with cladribine tablets beyond year 4 – second interim analysis of the CLIP-5 study

Catharina Korsukewitz, Nils Richter, Juliane Klehmet, Torsten Wagner et autres

Use of subcutaneous natalizumab in routine care – Final results of a non-interventional, observational study (SISTER) in Germany and Austria

Ralf Gold, Stephan Schmidt, Florian Deisenhammer, Jeremias Motte et autres

Background: Natalizumab is a disease-modifying therapy for patients with relapsing-remitting multiple sclerosis (RRMS). In addition to its original intravenous (IV) formulation, a subcutaneous (SC) route of administration (RoA) was approved in 2021. Subsequently, the observational SISTER study was initiated in Germany and …

de, at (code pays fourni par la source)

Development of a picture‐based tool for subjective deficits in cognition and ADLs

Isabell Ballasch, Ronja Faßbender, Oezguer A. Onur, Sophia Felicitas Schuh et autres

Abstract INTRODUCTION Traditional instruments assessing activities of daily living (ADLs) and cognitive complaints are language based and insufficiently capture technology‐based ADLs, limiting use among individuals with limited language proficiency or language impairments. We developed the picture‐based assessment of subjective deficits in cognition …

de (code pays fourni par la source)

Praxisbericht zur Nutzung von MTP in der Großchemie

Florian Pelzer, Dominik Thom, Veit Stooss, Matthias Roth et autres

Das Module Type Package (MTP) wird in der Großchemie bislang selten produktiv genutzt, bietet jedoch großes Potenzial für die Integration von Package Units in Prozessleitsysteme. Am Beispiel einer inhouse entwickelten Brenner-Unit wird gezeigt, dass eine vollständige softwareseitige Integration in unter 60 Minuten …

de, us (code pays fourni par la source)

Autonomie als Wettbewerbsfaktor

Michael I. Krauss, Marleen Stieler, Nils Richter, Thomas Scherwietes et autres

Die chemische Industrie steht vor enormen Herausforderungen: Niedrige Anlagenauslastung, hohe Energie- und Herstellkosten, sowie Regulierungsdruck, Fachkräftemangel und globale Konkurrenz. Klassische Sparprogramme leisten einen wichtigen Beitrag, reichen allerdings langfristig nicht mehr aus. Automatisierung und Autonomie sind zentrale Hebel für Effizienz, Flexibilität und Resilienz. …

us, de (code pays fourni par la source)

Detecting limbic predominant neurodegenerative co-pathologies in vivo in Alzheimer’s disease: magnetic resonance imaging markers, cognitive correlates, and prognosis

Nils Richter, Oezguer A. Onur, Gereon R. Fink

Abstract Background In Alzheimer’s disease (AD), limbic non-AD co-pathologies are common and contribute to memory impairment and accelerated clinical progression. To date, in vivo biomarkers of these co-pathologies are lacking. Here, we examined whether specific regional gray matter (GM) atrophy patterns on …

de (code pays fourni par la source)

Apraxic deficits predict general cognitive impairment in patients with biomarker-verified Alzheimer’s pathology

Claudia C. Schmidt, Michella M. Bardakan, Elena Jaeger, Nils Richter et autres

Apraxia represents a core feature of Alzheimer's disease (AD), a neurodegenerative disorder characterised by the accumulation of β-amyloid plaques and tau deposition. However, systematic descriptions of apraxic deficits in AD patients remain scarce. Here, we comprehensively investigate apraxia profiles and their link …

de (code pays fourni par la source)

Route-following deficits in amnestic mild cognitive impairment: Is the dual encoding of route-following strategies impaired?

Otmar Bock, Ju-Yi Huang, Maike Wigge, Chiara Bieche et autres

BackgroundOne of the earliest signs of amnestic mild cognitive impairment (MCI) and neurodegenerative dementia (ND) is spatial disorientation, e.g., getting lost on previously familiar routes. Healthy individuals often follow routes by combining two strategies, serial recall of directions and cue-direction associations, but …

de (code pays fourni par la source)

Alzheimer-typical temporo-parietal atrophy and hypoperfusion are associated with a more significant cholinergic impairment in amnestic neurodegenerative syndromes

Nils Richter, Laura Breidenbach, Maximilian H.T. Schmieschek, Wolf‐Dieter Heiss et autres

BackgroundTo date, cholinomimetics remain central in the pharmacotherapy of Alzheimer's disease (AD) dementia. However, postmortem investigations indicate that the AD-typical progressive amnestic syndrome may also result from predominantly limbic non-AD neuropathology such as TDP-43 proteinopathy and argyrophilic grain disease. Experimental evidence links …

de (code pays fourni par la source)

“Fill States”: PET-derived Markers of the Spatial Extent of Alzheimer Disease Pathology

Elena Doering, Merle C. Hoenig, Kathrin Giehl, Verena Dzialas et autres

The spatial extent of amyloid, tau, and neurodegeneration, derived from PET imaging, has higher diagnostic performance for cognitive impairment severity compared with standardized uptake value ratios.

de, us (code pays fourni par la source)

Detecting limbic predominant neurodegenerative co-pathologies in vivo in Alzheimer’s disease: magnetic resonance imaging markers, cognitive correlates, and prognosis

Nils Richter, Oezguer A. Onur, G FINK

In Alzheimer's disease (AD), limbic non-AD co-pathologies are common and contribute to memory impairment and accelerated clinical progression. To date, in vivo biomarkers of these co-pathologies are lacking. Here, we examined whether specific regional gray matter (GM) atrophy patterns on magnetic resonance …

de (code pays fourni par la source)

Alzheimer-typical temporo-parietal atrophy and hypoperfusion are associated with a more significant cholinergic impairment in amnestic neurodegenerative syndromes

Nils Richter, Laura Breidenbach, Maximilian H.T. Schmieschek, Wolf-Dieter Heiss et autres

BackgroundTo date, cholinomimetics remain central in the pharmacotherapy of Alzheimer's disease (AD) dementia. However, postmortem investigations indicate that the AD-typical progressive amnestic syndrome may also result from predominantly limbic non-AD neuropathology such as TDP-43 proteinopathy and argyrophilic grain disease. Experimental evidence links …

de (code pays fourni par la source)